SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than Nexavar in a Phase 3 trial.
Articles by Daniela Semedo, PhD
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver…
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has…
A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL).
Bozitinib (CBT-101) suppresses the growth of human liver tumors in a laboratory environment, according to its maker, CBT Pharmaceuticals.
Conatus Pharmaceuticals updated participants at two New York medical conferences this month on  its efforts to develop emricasan, which has…
CymaBay Therapeutics has named Sujal Shah as interim president and CEO following the retirement of Harold Van Wart, PhD. Robert Wills,…